Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

1. Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years

Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years 1 Published 10 June 2019 1 Product update SMC2178 fluticasone propionate/formoterol fumarate metered dose inhaler 50 microgram/5 microgram (flutiform®) Napp Pharmaceuticals Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/formoterol fumarate (flutiform®) is accepted for use within NHSScotland. Indication under review: the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting ß 2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting ß 2 agonist. Or • For patients

2019 Scottish Medicines Consortium

2. Efficacy and safety of fluticasone/salmeterol (Seretide) compared to montelukast (Singulair) in bronchial asthma in under-aged population: a systematic review and meta-analysis

Efficacy and safety of fluticasone/salmeterol (Seretide) compared to montelukast (Singulair) in bronchial asthma in under-aged population: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

3. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis (Full text)

NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis Chronic rhinosinusitis is common and sometimes complicated by nasal polyps (NPs). Corticosteroid nasal sprays are often unsatisfactory because they are ineffective at delivering medication to high/deep sites of inflammation.We sought to assess whether an exhalation delivery system with fluticasone (EDS-FLU) capable of high/deep drug deposition improves outcomes.Patients

2018 EvidenceUpdates PubMed

4. Fluticasone

Fluticasone Top results for fluticasone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluticasone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy)

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) Chronic obstructiv Chronic obstructive pulmonary disease: e pulmonary disease: fluticasone furoate, umeclidinium and vilanterol fluticasone furoate, umeclidinium and vilanterol (T (T relegy) relegy) Evidence summary Published: 14 June 2018 nice.org.uk/guidance/es18 pathways K Ke ey points y points The content of this evidence summary was up-to-date in June 2018. See summaries of product (...) characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory status: Regulatory status: Fluticasone furoate/umeclidinium/vilanterol (Trelegy, GlaxoSmithKline UK) received a European marketing authorisation in November 2017. This triple-therapy inhaler contains an inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA). It is licensed for maintenance treatment of adults with moderate- to-severe

2018 National Institute for Health and Clinical Excellence - Advice

6. Fluticasone/formoterol (flutiform k-haler) - for the regular treatment of asthma

Fluticasone/formoterol (flutiform k-haler) - for the regular treatment of asthma Abbreviated Submission fluticasone propionate/ formoterol fumarate 50microgram/5microgram, 125microgram/5microgram pressurised inhalation, suspension (Flutiform k-haler ® ) SMC2016 Napp Pharmaceuticals Ltd 4 May 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/ formoterol fumarate (Flutiform k-haler ® ) is accepted for use within NHS Scotland. Indication under review: for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting ß 2-agonist (LABA)] is appropriate: • For patients not adequately controlled with ICS as ‘as required’ inhaled short-acting ß2- agonist or • For patients already adequately controlled

2018 Scottish Medicines Consortium

7. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk (Full text)

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk Many patients with chronic obstructive pulmonary disease (COPD) have an accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients with moderately severe disease.In a prespecified analysis of the key secondary outcome in SUMMIT (Study to Understand Mortality and Morbidity), we investigated whether (...) the inhaled corticosteroid fluticasone furoate (FF; 100 μg), the long-acting β-agonist vilanterol (VI; 25 μg), or their combination (FF/VI) modified the rate of decline in FEV1 compared with placebo. We also investigated how baseline covariates affected this decline.Spirometry was measured every 12 weeks in this event-driven, randomized, placebo-controlled trial of 16,485 patients with moderate COPD and heightened cardiovascular risk. An average of seven spirometric assessments per subject among

2018 EvidenceUpdates PubMed

8. Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) Published 12 February 2018 Product Update fluticasone furoate, umeclidinium, vilanterol (as trifenatate) 92 micrograms / 55 micrograms / 22 micrograms inhalation powder (Trelegy ® Ellipta ® ) SMC No 1303/18 GlaxoSmithKline UK 12 January 2018 The Scottish Medicines Consortium (SMC) has completed its assessment (...) of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission fluticasone furoate / umeclidinium / vilanterol (as trifenatate) (Trelegy ® Ellipta ® ) is accepted for restricted use within NHS Scotland. Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated

2018 Scottish Medicines Consortium

9. fluticasone furoate/vilanterol (Breo Ellipta )

fluticasone furoate/vilanterol (Breo Ellipta ) fluticasone furoate/vilanterol | CADTH.ca Find the information you need fluticasone furoate/vilanterol fluticasone furoate/vilanterol Last Updated: December 14, 2017 Result type: Reports Project Number: SR0524-000 Product Line: Generic Name: fluticasone furoate/vilanterol Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: COPD Submission Type: Resubmission Project Status: Withdrawn Biosimilar: No Key Milestones 2 Call

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

10. fluticasone propionate / salmeterol xinafoate (RespiClick)

fluticasone propionate / salmeterol xinafoate (RespiClick) fluticasone propionate / salmeterol xinafoate | CADTH.ca Find the information you need fluticasone propionate / salmeterol xinafoate fluticasone propionate / salmeterol xinafoate Last Updated: March 22, 2019 Result type: Reports Project Number: SR0540-000 Product Line: Generic Name: fluticasone propionate / salmeterol xinafoate Brand Name: Arbesda RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma Submission Type: New (...) - Reconsideration requested Applicant's request for reconsideration placed on CDEC agenda December 12, 2018 CDEC Final Recommendation issued to applicant and drug plans December 19, 2018 CDEC Final Recommendation posted December 21, 2018 Final CADTH review report(s) and patient input posted January 17, 2019 Tags asthma, dry powder inhalers, respiratory, respiclick; arbesda; fluticasone propionate; salmeterol; dry powder inhaler; asthmatic; asthmatics Files Follow us: © 2019 Canadian Agency for Drugs

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

11. fluticasone propionate (RespiClick)

fluticasone propionate (RespiClick) fluticasone propionate | CADTH.ca Find the information you need fluticasone propionate fluticasone propionate Last Updated: December 21, 2018 Result type: Reports Project Number: SR0539-000 Product Line: Generic Name: fluticasone propionate Brand Name: Aermony RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: December 19, 2018 Recommendation Type (...) Recommendation posted December 21, 2018 Final CDR review report(s) and patient input posted January 21, 2019 Tags asthma, dry powder inhalers, respiratory, aermony; fluticasone propionate; dry powder inhaler; asthmatic; asthmatics; respiclick Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

12. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. (Full text)

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Evidence for management of asthma comes from closely monitored efficacy trials done in highly selected patient groups. There is a need for randomised trials that are closer to usual clinical practice.We did an open-label, randomised, controlled, two-arm effectiveness trial at 74 general practice clinics in Salford and South Manchester, UK (...) . Patients aged 18 years or older with a general practitioner's diagnosis of symptomatic asthma and on maintenance inhaler therapy were randomly assigned to initiate treatment with a once-daily inhaled combination of either 100 μg or 200 μg fluticasone furoate with 25 μg vilanterol or optimised usual care and followed up for 12 months. The primary endpoint was the percentage of patients who achieved an asthma control test (ACT) score of 20 or greater or an increase in ACT score from baseline of 3

2017 Lancet PubMed

13. Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma (Full text)

Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma To evaluate the dose-response, efficacy, and safety of fluticasone furoate (FF; 25 µg, 50 µg, and 100 µg), administered once daily in the evening during a 12-week treatment period to children with inadequately controlled asthma.This was a Phase IIb, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, placebo- and active-controlled study in children aged 5-11 years (...) with inadequately controlled asthma. The study comprised a 4-week run-in period, 12-week treatment period, and 1-week follow-up period. Children were randomized to receive either placebo once daily, fluticasone propionate (FP) 100 µg twice daily, FF 25 µg, FF 50 µg, or FF 100 µg each once daily in the evening. Primary endpoint was the mean change from baseline in daily morning peak expiratory flow (PEF) averaged over weeks 1-12. Adverse events (AEs) also were investigated.In total, 593 children were included

2016 EvidenceUpdates PubMed

14. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study (Full text)

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. Patients were randomised (1:1 (...) ) to aclidinium/formoterol 400/12 µg twice-daily via Genuair/Pressair or salmeterol/fluticasone 50/500 µg twice-daily via Accuhaler. The primary end-point was peak forced expiratory volume in 1 s (FEV1) at week 24. Other end-points included Transition Dyspnoea Index (TDI) focal score at week 24, TDI and St George's Respiratory Questionnaire (SGRQ) responders, COPD Assessment Test and SGRQ scores, assessment of COPD symptoms and exacerbations, use of reliever medication, and device preference. Adverse events

2016 EvidenceUpdates PubMed

15. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. (Full text)

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials to be conducted in conditions that are closer to usual clinical practice.In a controlled effectiveness trial conducted in 75 general practices, we randomly assigned 2799 (...) patients with COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 μg and vilanterol at a dose of 25 μg (the fluticasone furoate-vilanterol group) or to usual care (the usual-care group). The primary outcome was the rate of moderate or severe exacerbations among patients who had had an exacerbation within 1 year before the trial. Secondary outcomes were the rates of primary care contact (contact with a general practitioner, nurse, or other health care professional

2016 NEJM PubMed

16. Vilanterol and fluticasone furoate for asthma. (Full text)

Vilanterol and fluticasone furoate for asthma. Vilanterol (VI) is a long-acting beta2-agonist (LABA) that binds to the beta2-adrenoceptor on the airway smooth muscle, producing bronchodilation. LABA therapy, which is well established in adults as part of the British Thoracic Society (BTS) Guidelines for the Management of Asthma, leads to improvement in symptoms and lung function and reduction in exacerbations. At present, the commonly used LABAs licensed for use in asthma management (formoterol (...) overall.We included 10 comparisons in this review, seven for which the dose of VI and FF was 100/25 mcg (VI/FF 100/25 mcg vs placebo; VI/FF 100/25 mcg vs same dose of FF; VI/FF 100/25 mcg vs same dose of VI; VI/FF 100/25 mcg vs fluticasone propionate (FP) 500 mcg twice-daily; VI/FF 100/25 mcg vs fluticasone propionate/salmeterol (FP/SAL) 250/50 mcg twice-daily; VI/FF 100/25 mcg vs FP/SAL 250/25 mcg twice-daily; FF/VI 100/25 vs FP/SAL500/50) and three for which the dose of VI and FF was 200/25 mcg (VI/FF

2016 Cochrane PubMed

17. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. (Full text)

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in children.We (...) randomly assigned, in a 1:1 ratio, children 4 to 11 years of age who required daily asthma medications and had a history of asthma exacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization), as assessed in a time-to-event analysis. The statistical design specified that noninferiority would be shown if the upper boundary

2016 NEJM PubMed

18. Aerivio Spiromax (salmeterol xinafoate / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive

Aerivio Spiromax (salmeterol xinafoate / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 23 June 2016 EMA/486136/2016 Committee for Medicinal Products (...) for Human Use (CHMP) Assessment report Aerivio Spiromax International non-proprietary name: salmeterol / fluticasone propionate Procedure No. EMEA/H/C/002752/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/486136/2016 Page 2/50 Table of contents 1. Background information on the procedure 5 1.1. Submission of the dossier 5 1.2. Steps taken for the assessment of the product 7 2. Scientific discussion 8 2.1

2016 European Medicines Agency - EPARs

19. Airexar Spiromax (salmeterol / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive

Airexar Spiromax (salmeterol / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 June 2016 EMA/486131/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Airexar Spiromax International non-proprietary name: salmeterol (...) / fluticasone propionate Procedure No. EMEA/H/C/004267/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/486131/2016 Page 2/53 Table of contents 1. Background information on the procedure 6 1.1. Submission of the dossier 6 1.2. Steps taken for the assessment of the product 8 2. Scientific discussion 9 2.1. Introduction 9 2.2. Quality aspects 11 2.2.1. Introduction 11 2.2.2. Active substance 12 Fluticasone propionate

2016 European Medicines Agency - EPARs

20. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. (Full text)

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority (...) trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations.A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol

2016 NEJM PubMed